...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>JAIDS: Journal of acquired immune deficiency syndromes >The Chilean AIDS cohort: a model for evaluating the impact of an expanded access program to antiretroviral therapy in a middle-income country--organization and preliminary results.
【24h】

The Chilean AIDS cohort: a model for evaluating the impact of an expanded access program to antiretroviral therapy in a middle-income country--organization and preliminary results.

机译：智利AIDS队列：一种评估中等收入国家扩大获取计划对抗逆转录病毒疗法的影响的模型-组织和初步结果。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chile, middle-income country with 15 million people, began an expanded access program (EAP) to antiretroviral therapy (ART) in 2001. EAP provides ART, monitoring, and funding for management of associated complications in 32 points of care. A national cohort (Chilean AIDS Cohort [ChiAC]), enrolling 98% of these patients, was created for standardized treatment and impact evaluation. Information exchange is mainly through the Internet. By December 2004, the ChiAC had 4365 participants (83.3% male). At baseline, 47.5% had clinical AIDS, 26.2% were asymptomatic, 80.2% had a CD4 count <200 cells/mm and 58.2% were ART naive; in these patients, the most frequent regimen is zidovudine, lamivudine, and efavirenz. A 6-month follow-up in 1057 patients showed a global mortality of 5% (0.5% if patients were asymptomatic at baseline and 8.3% if patients had baseline AIDS). There was a similar risk of death if the baseline CD4 count was 100 to 200 cells/mm or >200 cells/mm ( approximately 1%), but this increased to 4.8% (relative risk [RR] = 5.2) and 10.7% (RR = 11.5) if the CD4 count was 51 to 100 cells/mm or
机译：智利是一个拥有1500万人口的中等收入国家，于2001年开始扩大抗逆转录病毒疗法（ART）的获取计划（EAP）。EAP为32个医疗点的相关并发症管理提供了ART，监测和资金支持。创建了一个全国性队列（智利艾滋病队列[ChiAC]），纳入了98％的这些患者，用于标准化治疗和影响评估。信息交换主要通过互联网进行。到2004年12月，ChiAC有4365名参与者（男性83.3％）。基线时，有47.5％的临床艾滋病，26.2％的无症状，80.2％的CD4计数＜200细胞/ mm和58.2％的未接受过ART。在这些患者中，最常用的方案是齐多夫定，拉米夫定和依非韦伦。对1057例患者进行的6个月随访显示，总体死亡率为5％（如果基线无症状，则为0.5％，基线AIDS为8.3％）。如果基线CD4计数为100至200个细胞/毫米或> 200个细胞/毫米（约1％），则存在类似的死亡风险，但这增加到4.8％（相对风险[RR] = 5.2）和10.7％（如果CD4计数分别为51至100细胞/ mm或<或= 50细胞/ mm，则RR = 11.5）。由于药物毒性，停药发生在7.7％的患者中，进展发生在2.9％的患者。借助中等收入国家的资源，成功的EAP到ART成为可能。早期结果与工业化国家相似。国家队列可以更好地实施和评估该计划，并且可能是其他国家的有用模型。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号